Click here for ReFacto AF® (moroctocog alfa) Prescribing Information. Adverse event reporting information can be found at the bottom of the page.
Reduction in annual bleed rate (ABR) vs on-demand in previously treated patients (PTPs). ReFacto AF prophylaxis is more effective at preventing bleeds than on-demand treatment, with an 85% reduction of bleeds per year (median ABR: 3.4; n=154)
achieved with prophylactic treatment3
of 10,882 bleeding episodes were treated effectively with only 1 infusion (n=113)1,2
of 2,715 bleeding episodes were treated effectively with only 1 infusion (n=101)1,2
of infusions administered were rated as excellent or good by the surgeon and treating physician (38 patients; 48 surgical procedures; 496 infusions during or after surgery)1,*
ReFacto AF is manufactured using the same cell line as ReFacto4 and is bioequivalent to ReFacto and pharmacokinetically equivalent to a full-length recombinant factor VIII (FLrFVIII) comparator5, so it is expected to behave in the same way.
*Excellent rating: achievement of comparable haemostasis to that expected after similar surgery in a non-haemophilic patient. Good rating: prolonged time to haemostasis with somewhat increased bleeding compared with that expected after similar surgery in a non-haemophilic patient.1
Speak to a member of the Pfizer Haemophilia team.
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-2688. December 2020